NVET: Nexvet Biopharma Public Limited Company - Summary | Jitta

Nexvet Biopharma Public Limited Company

NASDAQ:NVET

Notice
Stock data is unavailable or the company’s delisted.
Price
$6.72
Loss Chance
58.4%
0.50JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (25)
Recent Business Performance (15)
Financial Strength (0)
Return to Shareholders (0)
Competitive Advantage (0)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Recent IPOLess than 3 years
Operating MarginInconsistent
Key Stats
Jitta Score
Jitta Line
0.50
100.00%
2.22
131.45%
COMPANY DESCRIPTION
Nexvet Biopharma public limited company, a clinical-stage biopharmaceutical company, focuses on developing and commercializing species-specific biologics. Its product candidates include Ranevetmab, a monoclonal antibody (mAb) that targets and inhibits the function of nerve growth factor (NGF) for the control of pain associated with osteoarthritis in dogs; and Frunevetmab, a mAb that targets NGF inhibitor for the control of pain associated with degenerative joint disease, including osteoarthritis in cats. The company is also developing NV-03, a mAb targeting NGF that is being evaluated as a therapy for chronic joint pain in horses. In addition, it has research and development collaboration with Zenoaq for applying PETization technology to convert mAb candidates into species-specific candidates in the areas of immuno-oncology, inflammation, and allergy. Nexvet Biopharma public limited company is headquartered in Tullamore, Ireland. As of July 31, 2017, Nexvet Biopharma Public Limited Company operates as a subsidiary of Zoetis Inc.